OTC Markets OTCQX - Delayed Quote USD

CSL Limited (CSLLY)

77.50

-1.51

(-1.91%)

As of 2:32:38 PM EDT. Market Open.

Life Sciences Investor Forum: Now Available for Online Viewing

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.comNEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Sciences Investor Forum, held June 11th and 12th are now available for online viewing. REGISTER AND VIEW PRESENTATIONS The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may downloadinvestor

GlobeNewswire 6 hours ago

ATNM

STSS

STSSW
Life Sciences Investor Forum Agenda Announced for June 11th-12th

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.comNEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series announced the agenda for the Life Sciences Investor Forum June 11th & 12th. This event is co-hosted by Zacks Small Cap Research. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER HERE It is recommended that investors pre-register an

GlobeNewswire 3 days ago

CMXHF

CSLLY
-1.91%

VYCO
KMDA vs. CSLLY: Which Stock Should Value Investors Buy Now?

KMDA vs. CSLLY: Which Stock Is the Better Value Option?

Zacks 16 days ago

CSLLY
-1.91%

KMDA.TA
CSL (ASX:CSL) Secures NICE Approval For Sparsentan Use In NHS England

CSL (ASX:CSL) saw its stock price rise by 3% over the last month, amid important developments and a fluctuating market environment. CSL Vifor's notable progress with the National Institute for Health and Care Excellence recommending sparsentan for primary IgA nephropathy treatment may have provided positive momentum. This significant medical endorsement, alongside CSL's continued engagement with shareholders through meetings, could have added weight to its share performance. Meanwhile,...

Simply Wall St. 21 days ago

CMXHF

CSLLY
-1.91%
England's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy

CSL Vifor is pleased to announce that the National Institute for Health and Care Excellence (NICE) has published final draft guidance recommending that sparsentan can be used in the NHS in England as an option to treat primary IgA nephropathy in adults with a urine protein excretion of 1.0 g/day or more, or a urine protein-to-creatinine ratio of 0.75 g/g or more.3 NICE has provided guidance to ensure that only patients responding to treatment continue.3 The decision follows authorisation from th

PR Newswire 21 days ago

CMXHF

CSLLY
-1.91%

TVTX
CSL (ASX:CSL) Hosts Shareholder Information Meeting for Investor Clarity

Following a shareholder information meeting that updated stakeholders on performance and strategy, CSL (ASX:CSL) saw its share price rise by 5% over the past week. Despite the lack of specific earnings or dividend announcements, the meeting may have reinforced confidence among shareholders, contributing to the price increase. This move aligns with the broader market improvement, with the market climbing 3% over the same period. As investors weigh expected interest rate decisions and mixed...

Simply Wall St. last month

CMXHF

CSLLY
-1.91%
Australia's CSL evaluates China tariff exemptions for its US-made drugs

SHANGHAI (Reuters) -Australia's CSL Ltd said it's evaluating whether its drugs used in surgery would be exempted from 125% tariffs China imposed on U.S.-made goods, as it seeks to minimise impact of a trade war between Beijing and Washington. China has granted tariff exemptions on select products, including select pharmaceuticals, and has also created a non-public list of goods that would be exempted from duties, Reuters reported earlier on Wednesday, in the clearest sign yet of Beijing's concerns about the trade war's fallout. The quiet approach allows Beijing, which has repeatedly said it is willing to fight until the end unless the U.S. lifts its 145% tariffs on Chinese imports, to maintain its public messaging while privately taking practical steps to provide concessions.

Reuters last month

CSL.AX

GRFS
CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy

CSL Vifor and Travere Therapeutics, Inc., (NASDAQ: TVTX) are pleased to announce that the European Commission has approved the conversion of the conditional marketing approval (CMA) into a standard marketing authorization (MA) for FILSPARI for the treatment of adults with primary IgA nephropathy with a urine protein excretion ≥1.0 g/day (or urine protein-to-creatinine ratio ≥0.75 g/g). Standard MA is granted for all member states of the European Union, as well as in Iceland, Liechtenstein and No

PR Newswire last month

TVTX

CMXHF

CSLLY
-1.91%
Weekly Picks: 🧠 Alphabet’s AI edge, CSL’s pricing power, and a chip underdog

This week’s picks cover: Why Alphabet is the most undervalued Mag7 stock, how PVA TePLa is on the cusp of being re-rated higher, and why CSL is undervalued, no matter how high the tariffs go.

Simply Wall St. last month

GOOG

CMXHF

CSLLY
-1.91%
Are CSL Limited's (ASX:CSL) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?

CSL (ASX:CSL) has had a rough three months with its share price down 17%. However, stock prices are usually driven by a...

Simply Wall St. last month

CMXHF

CSLLY
-1.91%
BMRN vs. CSLLY: Which Stock Is the Better Value Option?

BMRN vs. CSLLY: Which Stock Is the Better Value Option?

Zacks 2 months ago

BMRN

CSL.AX
CSL initiated with an Overweight at Morgan Stanley

Morgan Stanley initiated coverage of CSL (CSLLY) with an Overweight rating and A$313 price target A “solid revenue growth outlook” and margin recovery for CSL Behring underpin group EPS growth of about 13% per year over the next three years, the analyst tells investors. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’ Hot Stocks on TipRanks >> Read More on CSLLY: Arcturus Therapeutics and CSL’s Kostaive COVID-19 vaccine

TipRanks 2 months ago

CMXHF

CSLLY
-1.91%
BMRN vs. CSLLY: Which Stock Should Value Investors Buy Now?

BMRN vs. CSLLY: Which Stock Is the Better Value Option?

Zacks 2 months ago

CSL.AX

BMRN
Only Two Days Left To Cash In On CSL's (ASX:CSL) Dividend

CSL Limited ( ASX:CSL ) stock is about to trade ex-dividend in 2 days. The ex-dividend date is usually set to be two...

Simply Wall St. 3 months ago

CMXHF

CSLLY
-1.91%
Esperion Partners with CSL Seqirus to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Australia

– Esperion to Receive an Upfront Payment and Near-Term Milestones Along with a Profitable Transfer Price on Product Sales –ANN ARBOR, Mich., March 03, 2025 (GLOBE NEWSWIRE) -- Esperion Therapeutics (NASDAQ: ESPR) today announced it has entered into a license and distribution agreement with CSL Seqirus (ASX:CSL) for the exclusive rights to commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Australia and New Zealand. Under the terms of the agreement, Esperion

GlobeNewswire 3 months ago

ESPR

CMXHF

CSLLY
-1.91%
BMRN or CSLLY: Which Is the Better Value Stock Right Now?

BMRN vs. CSLLY: Which Stock Is the Better Value Option?

Zacks 3 months ago

BMRN

CSL.AX
CSL Receives Approval in Japan for ANDEMBRY® (garadacimab) Subcutaneous (S.C.) Injection 200mg Pens, a Novel Human Anti-Activated Factor XII Monoclonal Antibody for the Prevention of Acute Attacks of Hereditary Angioedema (HAE)

CSL Behring K.K. (Headquarters: Minato-ku, Tokyo; President and Representative Director: Izumi Yoshida) today announced that it has received manufacturing and marketing approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for ANDEMBRY® (garadacimab) Subcutaneous (S.C.) Injection 200mg Pens. The product is approved for the prevention of acute attacks of hereditary angioedema (HAE) and is the first pre-filled pen presentation for once-monthly subcutaneous administration for long-ter

PR Newswire 3 months ago

CMXHF

CSLLY
-1.91%
Here's What Analysts Are Forecasting For CSL Limited (ASX:CSL) After Its Half-Yearly Results

CSL Limited ( ASX:CSL ) shareholders are probably feeling a little disappointed, since its shares fell 4.8% to AU$257...

Simply Wall St. 3 months ago

CMXHF

CSLLY
-1.91%
European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine

Global biotechnology leader CSL (ASX: CSL; USOTC: CSLLY) and sa-mRNA pioneer Arcturus Therapeutics (Nasdaq: ARCT) today announced that the European Commission has granted marketing authorization for KOSTAIVE ® (ARCT-154), a self-amplifying mRNA COVID-19 vaccine, for individuals 18 years and older. KOSTAIVE is the first sa-mRNA COVID-19 vaccine to receive approval from the European Commission (EC). KOSTAIVE is currently marketed in Japan against COVID-19.

PR Newswire 3 months ago

CMXHF

CSLLY
-1.91%

ARCT
European Commission Approves CSL's ANDEMBRY® (garadacimab) for the Prevention of Recurrent Attacks of Hereditary Angioedema (HAE)

Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced that the European Commission (EC) has approved ANDEMBRY® (garadacimab), the first and only once-monthly treatment targeting factor XIIa to prevent attacks of hereditary angioedema (HAE) in adult and adolescent patients aged 12 years and older. ANDEMBRY inhibits plasma protein factor XIIa, which initiates the cascade of events leading to angioedema at various sites of the body. ANDEMBRY reinforces CSL's decades-long commitment

PR Newswire 3 months ago

CMXHF

CSLLY
-1.91%

Performance Overview

Return	CSLLY	S&P/ASX 200 [XJO] (^AXJO)
YTD	-11.49%	+4.76%
1-Year	-18.12%	+10.29%
3-Year	-12.31%	+23.30%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

CSL Limited (CSLLY)

Life Sciences Investor Forum: Now Available for Online Viewing

Life Sciences Investor Forum Agenda Announced for June 11th-12th

KMDA vs. CSLLY: Which Stock Should Value Investors Buy Now?

CSL (ASX:CSL) Secures NICE Approval For Sparsentan Use In NHS England

England's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy

CSL (ASX:CSL) Hosts Shareholder Information Meeting for Investor Clarity

Australia's CSL evaluates China tariff exemptions for its US-made drugs

CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy

Weekly Picks: 🧠 Alphabet’s AI edge, CSL’s pricing power, and a chip underdog

Are CSL Limited's (ASX:CSL) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?

BMRN vs. CSLLY: Which Stock Is the Better Value Option?

CSL initiated with an Overweight at Morgan Stanley

BMRN vs. CSLLY: Which Stock Should Value Investors Buy Now?

Only Two Days Left To Cash In On CSL's (ASX:CSL) Dividend

Esperion Partners with CSL Seqirus to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Australia

BMRN or CSLLY: Which Is the Better Value Stock Right Now?

CSL Receives Approval in Japan for ANDEMBRY® (garadacimab) Subcutaneous (S.C.) Injection 200mg Pens, a Novel Human Anti-Activated Factor XII Monoclonal Antibody for the Prevention of Acute Attacks of Hereditary Angioedema (HAE)

Here's What Analysts Are Forecasting For CSL Limited (ASX:CSL) After Its Half-Yearly Results

European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine

European Commission Approves CSL's ANDEMBRY® (garadacimab) for the Prevention of Recurrent Attacks of Hereditary Angioedema (HAE)

Performance Overview